Edwards Lifesciences confident in sustainable growth with strong focus on structural heart market

Edwards Lifesciences CEO Bernard Zovighian expressed strong confidence in the company's future, highlighting strategic clarity and a focused approach on the structural heart market. The company reported a successful year with double-digit growth continuing into Q1, driven by broad-based performance across surgical TAVR, mitral, and tricuspid segments and multiple regions. The sale of its Critical Care business has enhanced agility and execution speed, contributing to sustainable and differentiated performance. Edwards Lifesciences expects this momentum to continue throughout the year.